RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlaxoSmithKline Pharmaceuticals Stock

GlaxoSmithKline Pharmaceuticals Stocks 2024

GlaxoSmithKline Pharmaceuticals Stocks

169.41 M

Ticker

GLAXO.NS

ISIN

INE159A01016

In 2024, GlaxoSmithKline Pharmaceuticals had 169.41 M outstanding stocks, a 0% change from the 169.41 M stocks in the previous year.

The GlaxoSmithKline Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined INR)
2027e169.41
2026e169.41
2025e169.41
2024169.41
2023169.41
2022169
2021169
2020169
2019169
2018169
2017169
2016169
2015169
2013169
2012169
2011169
2010169
2009169
2008169
2007169
2006169
2005172
2004175

GlaxoSmithKline Pharmaceuticals shares outstanding

The number of shares was GlaxoSmithKline Pharmaceuticals in 2023 — This indicates how many shares 169.406 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GlaxoSmithKline Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GlaxoSmithKline Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GlaxoSmithKline Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GlaxoSmithKline Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GlaxoSmithKline Pharmaceuticals Aktienanalyse

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline (GSK) is a global pharmaceutical company focused on the development, manufacturing, and marketing of prescription medicines, vaccines, and consumer products. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has become one of the leading players in the pharmaceutical and healthcare industry. GSK's history began in 1859 with the opening of a pharmacy in New Zealand by Joseph Edward Nathan. In 1904, physician and researcher Joseph Nathan Cohen founded Glaxo Laboratories, which specialized in the production of vitamin preparations. Over the years, the company expanded and eventually merged with Wellcome plc in 1995 to form Glaxo Wellcome. SmithKline Beecham was founded in 1830 and expanded through acquisitions and mergers in the following decades. In June 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK's business model is based on research, development, and marketing of products aimed at improving patients' lives. The company has a wide range of products, including prescription medicines, vaccines, and consumer products. GSK operates in over 100 countries and employs over 100,000 people worldwide. GSK has various divisions, including pharmaceuticals, vaccines, and consumer healthcare. The pharmaceutical division is the company's core business and focuses on researching and developing innovative therapies in the areas of oncology, immunology, infectious diseases, and respiratory diseases. The company's vaccine division is involved in vaccine production and the development of new vaccine technologies. GSK is one of the largest vaccine manufacturers globally and produces vaccines against infectious diseases such as hepatitis A and B, meningococcal disease, pneumococcal disease, and HPV. The company's consumer healthcare division produces a wide range of products in the health and wellness sector, including dietary supplements, pain relievers, and skincare products under brands like Sensodyne, Voltaren, and Aquafresh. Some of GSK's most well-known products include the antidepressant Paxil, the asthma inhaler Advair, and the antimalarial medication Malarone. Additionally, GSK has played a leading role in addressing global health issues, such as developing a vaccine against Ebola and providing antiretroviral drugs for the treatment of HIV/AIDS. Overall, GlaxoSmithKline has established a strong position as one of the leading global pharmaceutical companies in recent years. The company pursues an innovative research and development strategy to promote forward-looking technologies that have the potential to change the way we perceive and treat diseases. With a strong focus on innovation, growth, and improving the quality of life for patients worldwide, GSK is on track to remain a significant player in the global healthcare industry. GlaxoSmithKline Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating GlaxoSmithKline Pharmaceuticals's Shares Outstanding

GlaxoSmithKline Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in GlaxoSmithKline Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding GlaxoSmithKline Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in GlaxoSmithKline Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals stock

How many stocks are there of GlaxoSmithKline Pharmaceuticals?

The current number of stocks of GlaxoSmithKline Pharmaceuticals is 169.41 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of GlaxoSmithKline Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of GlaxoSmithKline Pharmaceuticals evolved in recent years?

The number of shares of GlaxoSmithKline Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. GlaxoSmithKline Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of GlaxoSmithKline Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does GlaxoSmithKline Pharmaceuticals pay?

Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 32 INR . This corresponds to a dividend yield of about 1.17 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.32 INR.

What is the dividend yield of GlaxoSmithKline Pharmaceuticals?

The current dividend yield of GlaxoSmithKline Pharmaceuticals is 1.17 %.

When does GlaxoSmithKline Pharmaceuticals pay dividends?

GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, August, July, June.

How secure is the dividend of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 23 years.

What is the dividend of GlaxoSmithKline Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 30.32 INR are expected. This corresponds to a dividend yield of 1.11 %.

In which sector is GlaxoSmithKline Pharmaceuticals located?

GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 7/1/2024 amounting to 32 INR, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did GlaxoSmithKline Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of GlaxoSmithKline Pharmaceuticals in the year 2023?

In the year 2023, GlaxoSmithKline Pharmaceuticals distributed 32 INR as dividends.

In which currency does GlaxoSmithKline Pharmaceuticals pay out the dividend?

The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GlaxoSmithKline Pharmaceuticals

Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.